Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”
05 5월 2022 - 5:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
the peer-reviewed publication of preclinical data demonstrating how
its lead product candidate, ATRC-101, activates the immune system
and drives tumor destruction in a Proceedings of the National
Academy of Sciences (PNAS) paper titled “Mobilization of Innate and
Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody
ATRC-101.”
"Immunotherapy approaches focusing on T cells have provided
breakthroughs in treating solid tumors, but there remains an
opportunity to drive anticancer immune responses via other immune
cell types, particularly myeloid cells of the innate immune
system,” said Tito A. Serafini, Ph.D., Chief Strategy Officer of
Atreca. “The preclinical data published in PNAS indicate that
ATRC-101 activates myeloid cells of the innate immune system via an
RNA-containing tumor target that we discovered via our platform,
leading eventually to an adaptive immune response that attacks
tumor, which is a novel mechanism of action for an oncology
therapeutic. Our data align well with how different RNA-containing
targets drive similar innate and adaptive immune responses
elsewhere in human biology. In March of this year, we presented
results from our ongoing clinical trial of ATRC-101 demonstrating
that anti-tumor activity is indeed associated with target
expression, and we look forward to presenting additional clinical
data later this year.”
The PNAS publication details the discovery and preclinical
development of ATRC-101, which was identified via a target-agnostic
process evaluating antibodies produced by the plasmablast
population of B cells in a patient experiencing an antitumor immune
response during treatment with checkpoint inhibitor therapy.
Immunohistochemistry studies demonstrated tumor-selective binding
of ATRC-101 to multiple non-autologous tumor tissues, and
biochemical analyses indicate that it targets an extracellular,
tumor-specific ribonucleoprotein (RNP) complex. Robust antitumor
activity and evidence of immune memory following rechallenge with
fresh tumor cells were observed in syngeneic murine models, as well
as an influx of conventional dendritic cell (cDC) type 1 cells in
the blood within 24 hours of dosing, increased CD8+ T cells and
natural killer (NK) cells in blood and tumor over time, decreased
cDC type 2 cells in the blood, and decreased monocytic
myeloid-derived suppressor cells in the tumor. Cellular stress,
including that induced by chemotherapy, increased the amount of
ATRC-101 target in tumor cells, and ATRC-101 combined with
doxorubicin enhanced efficacy compared with either agent alone.
“By leveraging the active human immune response to guide the
identification of tumor-selective antibodies, an approach conceived
by Atreca co-founder Dr. William Robinson, Professor of Immunology
and Rheumatology at Stanford, Atreca’s novel approach to drug
discovery has the potential to unlock a vast and diverse set of new
cancer targets.” said Lawrence Steinman, M.D., Professor of
Neurology and Neurological Sciences, Pediatrics, and Genetics,
Stanford University Medical School. “In the case of ATRC-101, the
approach delivered an antibody that appears to both bind a novel
target and act via a novel mechanism, a remarkable achievement
which we are pleased to have recognized in PNAS.”
About Atreca, Inc.
Atreca is a clinical-stage biopharmaceutical company developing
novel antibody-based immunotherapeutics generated by its
differentiated discovery platform. Atreca's platform allows access
to an unexplored landscape in oncology through the identification
of unique antibody-target pairs generated by the human immune
system during an active immune response against tumors. These
antibodies provide the basis for first-in-class therapeutic
candidates, such as our lead product candidate ATRC-101. A Phase 1b
study evaluating ATRC-101 in multiple solid tumor cancers is
currently enrolling patients. For more information on Atreca,
please visit www.atreca.com.
Forward-Looking Statements
This release contains forward-looking statements regarding our
strategy and future plans, including statements regarding the
development of ATRC-101 and our preclinical and clinical plans,
including our plans to present additional ATRC-101 clinical data,
the reports of our preclinical and clinical data, the potential of
our discovery platform to identify new cancer targets, and the
ability of our discovery platform to identify potentially valuable
therapeutic antibodies. These forward-looking statements include,
but are not limited to, statements about our plans, objectives,
representations and contentions and are not historical facts and
typically are identified by use of terms such as "potential” and
“presenting” and similar words, although some forward-looking
statements are expressed differently. Our actual results may differ
materially from those indicated in these forward-looking statements
due to risks and uncertainties related to the initiation, timing,
progress and results of our research and development programs,
preclinical studies, clinical trials, regulatory submissions, and
other matters that are described in our most recent Annual Report
on Form 10-K and Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) and available on the SEC's
website at www.sec.gov, including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Julia Fuller, 858-692-2001julia@fordhutmanmedia.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024